High-dose etoposide with G-CSF for mobilizing blood progenitor cells
Author Information
Author(s): EJ Kanfer, D McGuigan, D Samson, Z Abboudi, G Abrahamson, JF Apperley, S Chilcott, C Craddock, J Davis, C MacDonald, D Macdonald, E Olavarria, N Philpott, GJS Rustin, MJ Seckl, M Sekhar, S Stern, ES Newlands
Primary Institution: Imperial College School of Medicine at Charing Cross and Hammersmith Hospitals
Hypothesis
Does reducing the dose of etoposide lessen toxicity without significantly affecting the effectiveness of mobilization?
Conclusion
High-dose etoposide with G-CSF is effective for mobilizing blood progenitor cells, with the lowest toxicity observed at a dose of 1.6 g m-2.
Supporting Evidence
- 63 patients were enrolled in the study.
- 84% of patients successfully mobilized PBPCs.
- Median CD34+ cell collections were higher in the lower dose groups.
Takeaway
This study shows that giving a lower dose of a cancer drug can help collect important blood cells with less side effects.
Methodology
A non-randomized sequential study where patients received etoposide at three different doses followed by G-CSF, and their blood cell collections were measured.
Potential Biases
Potential bias due to the non-randomized design and the specific patient population studied.
Limitations
The study was non-randomized and included a small sample size of patients who were heavily pretreated.
Participant Demographics
63 patients with malignancy, predominantly male (75%), aged 16 to 70 years, most had received multiple prior chemotherapy regimens.
Statistical Information
P-Value
0.03
Statistical Significance
p=0.03
Want to read the original?
Access the complete publication on the publisher's website